文献速递白血病淋巴瘤MDS 与骨髓增殖性肿瘤

慢性淋巴细胞白血病患者中的髓系不确定潜能的克隆性造血

Myeloid clonal hematopoiesis of indeterminate potential in patients with chronic lymphocytic leukemia.
PubMed 文献 · Blood Adv · 2024-01-01

该回顾性研究分析了966例在Dana-Farber癌症研究所前瞻性CLL数据库中有95基因NGS检测结果的患者,描述髓系CHIP(M-CHIP)的患病率及其与首次治疗时间和总生存的关系。未治疗和已治疗患者的M-CHIP患病率分别为12%和24%。≥2个M-CHIP突变与OS相关(校正治疗和年龄后),但由小部分患者(n=28)驱动;M-CHIP与TTFT无关。

要点

  • 未治疗和已治疗CLL患者的M-CHIP患病率分别为12%和24%。
  • ≥2个M-CHIP突变与总生存相关,但仅由28例患者驱动。
  • M-CHIP与首次治疗时间无关。

核心结论

  • 在CLL患者中,≥2个M-CHIP突变与OS相关(校正既往治疗和年龄后),但该关联由小部分患者(n=28)驱动。
  • M-CHIP与TTFT无关。
  • 这些发现支持继续研究M-CHIP在CLL患者中的影响。

研究设计与样本

  • 回顾性分析参与Dana-Farber癌症研究所前瞻性CLL数据库、并接受标准诊疗相关95基因NGS检测的患者数据。
  • 共纳入966例患者,NGS时中位年龄65岁,女性占38%。
  • 747例(77%)在CLL治疗前接受NGS,219例(23%)在治疗后接受NGS。
  • 从NGS起中位随访时间为1.9年。

主要发现

  • 未治疗患者M-CHIP患病率为12%,已治疗患者为24%。
  • 未治疗患者中M-CHIP患病率似乎随年龄增加,而已治疗患者中各年龄患病率似乎一致,提示治疗(85%有既往化疗)可能影响M-CHIP出现,即使在年轻患者中。
  • ≥2个M-CHIP突变与OS相关(校正既往治疗和年龄后),但由小部分患者(n=28)驱动。
  • M-CHIP与TTFT无关。

关键数值与推荐

  • M-CHIP作为二分类(有/无)和分类变量(≥2 vs 1 vs 0个突变)分析。
  • 未治疗患者M-CHIP患病率12%,已治疗患者24%。
  • 已治疗患者中85%有既往化疗。
  • ≥2个M-CHIP突变与OS相关(校正既往治疗和年龄后),由n=28例患者驱动。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Clonal hematopoiesis of indeterminate potential (CHIP) in patients with chronic lymphocytic leukemia (CLL) has not been extensively characterized. The objective of this study was to describe the prevalence of myeloid CHIP (M-CHIP) in patients with CLL, and to determine its association with time to first treatment (TTFT) and overall survival (OS). We retrospectively analyzed data from patients participating in a prospective CLL database at the Dana-Farber Cancer Institute who had standard-of-care targeted 95-gene next-generation sequencing (NGS) performed. A schema was devised to classify mutations as M-CHIP related. M-CHIP was analyzed as a binary (present/absent) and categorical (≥2 vs 1 vs 0 mutations) predictor. We included 966 patients (median age at time of NGS, 65 years; 38% female). Overall, 747 (77%) patients had NGS performed before CLL treatment, whereas 219 (23%) had it performed after receiving treatment. Median follow-up time from NGS was 1.9 years. The prevalence of M-CHIP in untreated (12%) and treated (24%) patients with CLL was similar to that described in previous literature. M-CHIP prevalence appeared to increase with age in untreated patients, but appeared consistent across age in treated patients, suggesting that treatment (85% had prior chemotherapy) may have an impact on M-CHIP emergence even in younger patients. The presence of ≥2 M-CHIP mutations was associated with OS, even accounting for prior treatment and age, but was driven by a small subset of patients (n = 28). M-CHIP was not associated with TTFT. These findings support continued work into characterizing the effects of M-CHIP in patients with CLL.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Vijenthira A, Volpe VO, Sekar A, et al. Myeloid clonal hematopoiesis of indeterminate potential in patients with chronic lymphocytic leukemia. Blood Adv. 2024. PMID: 39321421. doi:10.1182/bloodadvances.2024013414

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。